Odysseas Kostas D 4

What Happened Odysseas Kostas D, a director of Armata Pharmaceuticals, was granted a derivative award of stock options covering 25,640 shares. The Form 4 records the acquisition at $0.00 (derivative), i.e., an award/grant rather than a purchase or sale.

Key Details

• Transaction date: March 9, 2026
• Nature: Grant / Award of Stock Options (transaction code A)
• Amount: 25,640 option shares; reported price $0.00 (derivative; value not reported as cash)
• Vesting footnote: Options vest in full on March 9, 2027, subject to continuous service (Footnote F1)
• Shares owned after transaction: not specified in the provided filing
• Filing date: March 11, 2026 — filed two days after the reported transaction (appears timely under standard Section 16 reporting rules)

Context This was an equity award to a board director, a common form of director compensation. No exercise or sale occurred — the grant will only convert to actual shares if the options vest and are later exercised. Such grants are routine and do not by themselves indicate an insider buying or selling stock.